3 Analysis of Exhaled Volatile Organic Compounds: A New Frontier in Breast Cancer Screening and Surveillance

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1

Alexandra Allard-Coutu BSc, MDCM, FRCSC1; Kevin Singh BSc, MDCM, FRCPC2; André Lamontagne3; Yves Gamache3; Nicole Hodgson MD, FRCSC1; Peter Lovrics MD, FRCSC1; Susan Reid MD, FRCSC1; Barbara Heller MD, FRCSC1

1McMaster University, Hamilton, Ontario, Canada

2University of Toronto, Ontario, Canada

3eTrace Medical, Montreal, Quebec, Canada

Background

Neoplastic processes cause distinct and immediate changes to the body’s metabolism, creating unique patterns in the volatile organic compounds (VOCs) being produced and released. Unique VOC profiles have been shown to be diagnostic for certain cancers. Exhaled breath VOC analysis has potential as a point-of-care tool for screening a wide range of cancers in a single sample. This technology can also be used to monitor response to treatment and can be applied to posttreatment cancer surveillance protocols.

Methods

An exhaled breath VOC analyzer was developed based on ASDevices and eTrace Medical patented technology. Proof-of-principle experiments established a detection limit and sensitivity/specificity of the Epd sensing technology. A case-control trial is underway to validate the device using 25 exhaled VOCs previously shown to be diagnostic for breast cancer, and assess whether eTrace Medical’s AeolCare point-of-care exhaled breath analyzer accurately predicts a diagnosis of breast cancer in female patients referred for breast biopsy, following abnormal imaging (BI-RADS 3-5) or detection of a palpable breast mass. The ability of the VOC profile to reliably detect breast cancer will be evaluated by receiver operating characteristic curve analysis, followed by cross validation by the leave-one-out method and stepwise logistic regression analysis.

Preliminary Results

Using representative biomarkers in exhaled breath, proof-of-principle testing confirmed the sensitivity and selectivity of the sensing technology based on a proprietary gas chromatography (GC) method from eTrace Medical (patent pending). Protocol validation included testing of ASDevices technologies (pretreatment and concentrator, iMov GC platform, uInProve GC valve, and Epd sensing technologies) (Figure A). Targeted molecules (sulfur, benzene, toluene, and xylene) were contained in an air matrix to simulate exhaled breath. This validation system demonstrated that the device can reliably measure targeted molecules at levels within 10 ppb of their nominal value (Figure B). The detection limit, based on 3Å~ signal:noise ratio, was between 200 and 700 ppt. The sensitivity of the system can be further adapted via sample concentration and pretreatment.

FIGURE

FIGURE

Conclusion

There is strong evidence to support the use of VOCs in exhaled breath to accurately detect breast cancer. The implementation of VOC analysis for accessible screening and early detection of breast cancer could improve patient outcomes and reduce the number of breast cancer–related deaths, as well as the global disease burden. We propose a proof-of-concept case-control study to determine the sensitivity and specificity of exhaled breath analysis, using a novel point-of-care tool for the diagnosis of breast cancer and previously described VOC breath prints.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients